

UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. KING G 10276-026001

03/10/00 09/524,459

FISH & RICHRDSON P C

225 FRANKLIN STREET BOSTON MA 02110-2804

11

P LOUIS MYERS

HM12/0105

EXAMINER

JONES, D

ART UNIT PAPER NUMBER

1614

DATE MAILED:

01/05/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/524,459

Applic s)

King

Examiner

Dwayne C. Jones

Group Art Unit 1614



Responsive to communication(s) filed on	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for form in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.E.	nal matters, prosecution as to the merits is closed D. 11; 453 O.G. 213.
A shortened statutory period for response to this action is set to expis longer, from the mailing date of this communication. Failure to reapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	pire3month(s), or thirty days, whichever
Disposition of Claims	·
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration
Claim(s)	is/are allowed.
	is/are rejected
Claim(s)	is/are objected to
☐ Claims	are subject to restriction or election requirement
Application Papers	are subject to restriction or election requirement.
See the attached Notice of Draftsperson's Patent Drawing Revi	io DTO 040
☐ The drawing(s) filed on	
☐ The proposed drawing correction, filed on	. —
☐ The specification is objected to by the Examiner.	_is Lapproved Ldisapproved.
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority under	25 H.C.C. & 110(a) (d)
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the p	oriority documents have been
received.	monty documents have been
received in Application No. (Series Code/Serial Number)	
received in this national stage application from the Intern	ational Bureau (PCT Rule 17.2(a))
*Certified copies not received:	
Acknowledgement is made of a claim for domestic priority unde	er 35 U.S.C. § 119(e).
Attachment(s)	·
☑ Notice of References Cited, PTO-892	
☑ Information Disclosure Statement(s), PTO-1449, Paper No(s)	5
☐ Interview Summary, PTO-413	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE FOL	LOWING PAGES

Application/Control Number: 09/524,459

Page 2

Art Unit: 1614

DETAILED ACTION

Status of Claims

- 1. Claims 1-24 are pending.
- 2. Claims 1-24 are rejected.

Information Disclosure Statement

3. The information disclosure statement filed December 19, 2000 has been reviewed and considered, see enclosed copy of PTO FORM 1449.

Drawings

4. This application has been filed with informal drawings which are acceptable for examination purposes only. Formal drawings will be required when the application is allowed.

Claim Rejections - 35 USC § 102

- 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
 - A person shall be entitled to a patent unless --
 - (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Art Unit: 1614

6. Claims 1, 2, 16, 17 and 23 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Sittler et al. teach of of a peritonieal dialysis fluid which contains D-glucose and a protein kinase C (PKC) inhibitor Ro 31-8220.

Claim Rejections - 35 USC § 103

- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 8. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 9. Claims 1-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sitter et al. Sittler et al. teach of of a peritonieal dialysis fluid which contains D-glucose and a protein kinase C (PKC) inhibitor Ro 31-8220. Sitter et al. are silent to other inhibitors of PKC. Although Sitter et al. do not teach of other inhibitors of PKC it would have been obvious to one having ordinary skill in the art to substitute one PKC inhibitor for another since Sitter et al. are directed to

Application/Control Number: 09/524,459

Page 4

Art Unit: 1614

prostaglandin E_2 synthesis. Surely, the prior art reference of Sitter et al. render the instant invention obvious especially when the instant claims are only directed to generic methods of treating and to a peritonical dialysis fluid.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-1235.

Tech. Ctr. 1614

January 4, 2000